

Radiomics: the process and the challenges

Virendra Kumar^a, Yuhua Gu^a, Satrajit Basu^b, Anders Berglund^c, Steven A. Eschrich^c,
Matthew B. Schabath^d, Kenneth Forster^e, Hugo J.W.L. Aerts^{f,h}, Andre Dekker^f,
David Fenstermacher^c, Dmitry B. Goldgof^b, Lawrence O. Hall^b, Philippe Lambin^f,
Yoganand Balagurunathan^a, Robert A. Gatenby^g, Robert J. Gillies^{a,g,*}

^aDepartment of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

^bDepartment of Computer Science and Engineering, University of South Florida, Tampa, FL, USA

^cDepartment of Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

^dDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

^eDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

^fDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology,
Maastricht University Medical Center, Maastricht, the Netherlands

^gDepartment of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

^hComputational Biology and Functional Genomics Laboratory, Department of Biostatistics and Computational Biology,
Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA

Received 23 March 2012; revised 19 June 2012; accepted 21 June 2012

Abstract

“Radiomics” refers to the extraction and analysis of large amounts of advanced quantitative imaging features with high throughput from medical images obtained with computed tomography, positron emission tomography or magnetic resonance imaging. Importantly, these data are designed to be extracted from standard-of-care images, leading to a very large potential subject pool. Radiomics data are in a mineable form that can be used to build descriptive and predictive models relating image features to phenotypes or gene–protein signatures. The core hypothesis of radiomics is that these models, which can include biological or medical data, can provide valuable diagnostic, prognostic or predictive information. The radiomics enterprise can be divided into distinct processes, each with its own challenges that need to be overcome: (a) image acquisition and reconstruction, (b) image segmentation and rendering, (c) feature extraction and feature qualification and (d) databases and data sharing for eventual (e) ad hoc informatics analyses. Each of these individual processes poses unique challenges. For example, optimum protocols for image acquisition and reconstruction have to be identified and harmonized. Also, segmentations have to be robust and involve minimal operator input. Features have to be generated that robustly reflect the complexity of the individual volumes, but cannot be overly complex or redundant. Furthermore, informatics databases that allow incorporation of image features and image annotations, along with medical and genetic data, have to be generated. Finally, the statistical approaches to analyze these data have to be optimized, as radiomics is not a mature field of study. Each of these processes will be discussed in turn, as well as some of their unique challenges and proposed approaches to solve them. The focus of this article will be on images of non-small-cell lung cancer.

© 2012 Elsevier Inc. All rights reserved.

Keywords: Radiomics; Imaging; Image features; Tumor; Segmentation

1. Introduction

“Radiomics” involves the high-throughput extraction of quantitative imaging features with the intent of creating

mineable databases from radiological images [1]. It is proposed that such profound analyses and mining of image feature data will reveal quantitative predictive or prognostic associations between images and medical outcomes. In cancer, current radiological practice is generally qualitative, e.g., “a peripherally enhancing spiculated mass in the lower left lobe.” When quantitative, measurements are commonly limited to dimensional measurements of tumor size via one-dimensional (Response Evaluation Criteria In Solid Tumors

* Corresponding author. Cancer Imaging and Metabolism, Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Tel.: +1 813 745 8355; fax: +1 813 745 7265.

E-mail address: robert.gillies@moffitt.org (R.J. Gillies).

[RECIST]) or two-dimensional (2D) (World Health Organization) long-axis measures [2]. These measures do not reflect the complexity of tumor morphology or behavior, nor, in many cases, are changes in these measures predictive of therapeutic benefit [3]. When additional quantitative measures are obtained, they generally average values over an entire region of interest (ROI).

There are efforts to develop a standardized lexicon for the description of such lesions [4,5] and to include these descriptors via annotated image markup into quantitative, mineable data [6,7]. However, such approaches do not completely cover the range of quantitative features that can be extracted from images, such as texture, shape or margin gradients. In focused studies, texture features have been shown to provide significantly higher prognostic power than ROI-based methods [8–11]. The modern rebirth of radiomics (or radiogenomics) was articulated in two papers by Kuo and colleagues. Following a complete manual extraction of numerous (>100) image features, a subset of 14 features was able to predict 80% of the gene expression pattern in hepatocellular carcinoma using computed tomographic (CT) images [12]. A similar extraction of features from contrast-enhanced magnetic resonance images (MRI) of glioblastoma was able to predict immunohistochemically identified protein expression patterns [13]. Although paradigm shifting, these analyses were performed manually, and the studies were consequently underpowered. In the current iteration of radiomics, image features have to be extracted automatically and with high throughput, putting a high premium on novel machine learning algorithm development.

The goal of radiomics is to convert images into mineable data, with high fidelity and high throughput. The radiomics enterprise can be divided into five processes with definable inputs and outputs, each with its own challenges that need to be overcome: (a) image acquisition and reconstruction, (b) image segmentation and rendering, (c) feature extraction and feature qualification, (d) databases and data sharing and (e) ad hoc informatics analyses. Each of these steps must be developed de novo and, as such, poses discrete challenges that have to be met (Fig. 1). For example, optimum protocols for image acquisition and reconstruction have to be identified and harmonized. Segmentations have to be robust and involve minimal operator input. Features have to be generated that robustly reflect the complexity of the individual volumes, but cannot be overly complex or redundant. Informatics databases that allow for incorporation of image features and image annotations, along with medical and genetic data, have to be generated. Finally, the statistical approaches to analyze these data have to be optimized, as radiomics is not a mature field of study. Variation in results may come from variations in any of these individual processes. Thus, after optimization, another level of challenge is to harmonize and standardize the entire process, while still allowing for improvement and process evolution.




Fig. 1. The process and challenges in radiomics.

2. Image acquisition and reconstruction challenges

In routine clinical image acquisition, there is wide variation in imaging parameters such as image resolution (pixel size or matrix size and slice thickness), washout period in the case of positron emission tomography (PET) imaging, patient position, and the variations introduced by different reconstruction algorithms and slice thicknesses, which are different for each scanner vendor. Even this simple set of imaging issues can create difficulty in comparing results obtained across institutions with different scanners and patient populations. In addition, it is a challenge to identify and curate a large number of image data examples with similar clinical parameters such as disease stage.

2.1. Image acquisition and reconstruction

2.1.1. CT

Of all the imaging modalities, CT appears to be the most straightforward and perhaps the easiest to compare across



Fig. 2. The CT phantom. This phantom has several regions to test image quality such as low contrast detectability and spatial resolution.

institutions and vendors. Standard phantoms such as the CT phantom have become the standard of the industry (Fig. 2). The phantom is based on the American Association of Physicists in Medicine (Task Group Report-1) and has several sections to evaluate imaging performance. There are sections (a) to evaluate the true slice thickness and variation

of Hounsfield units (HUs) with electron density, (b) to look at the ability to visualize small variations in density (low contrast detectability) and another (c) for detecting special resolution, high contrast detectability, and a region of uniform medium to examine variation in HUs. The imaging performance of a scanner will depend also on the imaging technique. As the slice thickness is reduced, the photon statistics within a slice are reduced unless the mA or kVp is increased. The axial field of view will also change the voxel size within a slice, and the reconstruction matrix size can also be varied from 512×512 up to 1024×1024, which also changes the voxel size.

Pitch is a parameter that is frequently optimized by each scanner manufacturer so that only certain pitches are allowed for an image acquisition. These pitches are unique to each scanner, and as a result, comparing noise between scanners can only be performed by investigating images acquired using axial, as opposed to helical or spiral, acquisitions. However, helical image acquisitions are used most often in a clinical setting. HUs can also vary with reconstruction algorithm. A single acquisition of a thoracic tumor is shown in Fig. 3A and B using two different reconstruction algorithms. While this is a single data acquisition, there are significant variations in tumor texture between the two images. The variation in HUs or texture along the vertical




Fig. 3. Effect of two different reconstruction algorithms on same raw CT data (A and B) where panel (A) shows a “standard smooth image” and panel (B) shows the same raw data reconstructed using a higher contrast algorithm. To appreciate the effect of these reconstruction algorithms, the profiles (in HUs) along the vertical lines are shown (C and D, respectively). Even the average HUs in the tumor are different for the different algorithms.

paths in Fig. 3A and 3B is shown on the graphs (Fig. 3C and 3D, respectively).

For clinical trials, significant effort will be required to match reconstruction protocols and image noise between scanners. While the CAT phantom is a reasonable initial step to compare different scanners, more sophisticated phantoms may be required to match the effects of reconstruction algorithms. Although there can be some variation, different vendors have algorithms that are similar enough to be quantitatively comparable. Indeed, the focus of our approach is to use features with (a) sufficient dynamic range between patients, (b) inpatient reproducibility and (c) insensitivity to image acquisition and reconstructions protocol.

2.1.2. PET-CT

Quantitative imaging with 2-deoxy-2- ^{18}F fluoro-D-glucose (18-FDG) PET scans is a challenge because it not only requires calibration of the scanner and standardization of the scan protocol but also requires the patient and staff to adhere to a strict patient protocol [14,15]. From a technical viewpoint, the main challenges are the dose calibration and the metabolic volume or volume-of-interest (VOI) reconstruction that depends heavily on the scan protocol and source-to-background ratio [16]. Before a scanner is used in a quantitative manner, interinstitution cross-calibration and quality control such as proposed recently [14] are necessary (Fig. 4). From a patient protocol perspective, administration issues (residual activity in syringe, paravenous administration), blood glucose level [17], uptake period, breathing, patient comfort and inflammation all influence the quantitation of the standardized uptake value (SUV) of 18-FDG. Complying with a strict protocol such as has been proposed by the Society of Nuclear Medicine and the European Association of Nuclear Medicine is another prerequisite to quantitative PET imaging.

2.1.3. MRI

The signal intensities in MR images arise from a complex interplay of inherent properties of the tissue, such as

relaxation times and acquisition parameters. Therefore, it is difficult to derive information about the physical properties of tissue from MR image signal intensities alone. This is in contrast to CT images where signal intensity can be correlated with the density of the tissue. However, certain techniques, such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI, allow assessment of physiological properties of tissue. For example, the apparent water diffusion coefficient determined using DWI varies inversely with tissue cellularity. DCE can be used to extract vascular flow, permeability and volume fractions. Although both of these techniques provide quantitative information, their reliability and reproducibility remain dependent on acquisition parameters and conditions. DW images can be of low spatial resolution and are sensitive to motion and magnetic susceptibility, and the quantitation is dependent on k-space trajectory, gradient strengths and b -values. DWI has been proposed as a cancer imaging biomarker, and there are efforts to develop quality control protocols [18,19]. Results of the DCE MRI depend on the contrast agent dose, method of administration, pulse sequence used, field strength of the scanner and the analysis method used [20–22]. Different investigators use different methods to convert DCE MRI signal intensities to contrast agent concentration [23–25]. Recently, a group of the Radiological Society of North America known as the Quantitative Imaging Biomarker Alliance initiated a standardization of the protocol for DCE MRI [26].

Ideally, MR images will all have the same field of view, field strength and slice thickness. Where possible, e.g., brain tumors, multiple sequences with contrast enhancement such as T1-weighted, T2-weighted and Fluid attenuated inversion recovery (FLAIR) can be very useful. In MR images of human brain tumors, radiomics has the potential to play an important role in categorizing the tumor. It is possible to view the tumor as having different regions using image features, including texture, wavelets, etc. For example, there will be areas of enhancement and potentially necrosis. The tumor bed can be extracted as an expanded region around the postcontrast T-weighted image, for example. Unsupervised clustering can be used to group the data into regions using data from multiple registered sequences. The extraction of image features from those regions, including such things as their location within the tumor bed, can allow for new types of tumor characterization. It has been observed that enhancement in individual tumors can be heterogeneous and that analysis of this heterogeneity has prognostic value [9]. The location and characteristics of such regions have the potential to provide new insights into tumor prognosis and how well it is likely to respond to targeted treatments. The opportunity to acquire images over time will allow for comparisons and contrasts between regions.

2.2. Need for large image data sets

The acquisition of images is time consuming and costly. Because of this, our approach is to focus on standard-of-care




Fig. 4. Metabolic volume calibration; PET phantom with differently sized sphere sources filled with FDG activity within a background activity. By varying the source-to-background-activity ratio, the capability of the PET scanner to reconstruct the correct sphere volume can be quantified.

images, with the expectation that this will generate large data sets and have more clinical impact compared to more controlled and dedicated prospective image acquisitions. Radiomics requires large image data sets with the expectation that large numbers may be able to overcome some of the heterogeneities inherent in clinical imaging. Image data sharing across sites will be important to make large data sets available for radiomics analysis.

Various online repositories are available that host image data. The image data contains the image series for each patient and each series containing image slices. One of the largest online CT image repositories is the National Biomedical Image Archive (NBIA) hosted by the National Cancer Institute. Apart from the images, image annotations and outcomes data are also important components to share. There should be a uniform image annotation format which could be read by other users to compare with their own segmentations. This format should support multiple annotations from alternative image analysis algorithms to support higher-level processing and prediction. The image data are linked to the metadata in DICOM-format images; the metadata contain information about the acquisition, scanner and other details of the images. Currently available clinical image data which may be used for radiomics study includes the Lung Image Database Consortium, the Reference Image Database to Evaluate Response to therapy in lung cancer and others [27,28]. Radiomics analyses require refined image data based on image characteristics (resolution, reconstruction and acquisition parameters) and clinical parameters (stage of disease, type of disease and outcomes).

A major use of the information extracted from CT scan images and clinical data is the development of automated prediction models. A challenge in modeling any classifier is making it robust enough for clinical use. Development of robust models requires a sufficiently robust training set. The lack of standardization in imaging makes it difficult to

determine the effectiveness of image features being developed and prediction models built to work on those feature values. A snapshot of the extent of the lack of standardization in image acquisition and reconstruction can be seen in Fig. 5. This figure represents the variation in slice thickness and pixel size (in mm) for a data set of CT scan images from 74 patients used by Basu et al. [29] to develop prediction models for classifying non-small-cell lung cancer (NSCLC) tumor types using image features. This variation affects the information being extracted by image feature algorithms, which in turn affects classifier performance. In this scenario, without the presence of a large standardized repository, setting performance benchmarks for effectiveness of image feature algorithms and classifier models built upon those features becomes difficult.

3. Segmentation challenges

Segmentation of images into VOIs such as tumor, normal tissue and other anatomical structures is a crucial step for subsequent informatics analyses. Manual segmentation by expert readers is often treated as ground truth. However, it suffers from high interreader variability and is labor intensive; thus, it is not feasible for radiomics analysis requiring very large data sets. Many automatic and semiautomatic segmentation methods have been developed across various image modalities like CT, PET and MRI and also for different anatomical regions like the brain, breast, lung, liver, etc. Though different image modalities and organ systems require ad hoc segmentation approaches, all share a few common requirements. The segmentation method should be as automatic as possible with minimum operator interaction, should be time efficient, and should provide accurate and reproducible boundaries. Most common segmentation algorithms used for medical images include




Fig. 5. The variation in slice thickness (A) and pixel size (B) for a data set of 74 patients.

region-growing-based methods (click-and-grow), level sets and graph cuts. Region-growing methods require an operator to select a seed point within the VOI. While these methods are most suitable for relatively homogenous regions, they can be user dependent and often introduce significant interobserver variation in the segmentations. We describe here some major challenges encountered while developing segmentation methods for NSCLC.

3.1. Challenges in segmentation of lung tumors

The segmentation of CT thorax images usually requires segmentation of lung fields for successive segmentation of lung nodules. Right and left lungs should be automatically segmented, which may serve as a preprocessing step. This has been achieved relatively successfully; however, in cases where high-intensity tumors are attached to the pleural wall or mediastinum, automatic segmentation often underperforms (Fig. 6). In our experience, while using rule-based methods, automatic segmentations often failed in such cases, as evidenced by extension of lung boundaries into the mediastinum or heart.

A majority of Stage I and Stage II NSCLC nodules present as homogenous, high-intensity lesions on a background of low-intensity lung parenchyma. These can be segmented with high reproducibility and accuracy. However, partially solid, ground glass opacities, nodules attached to vessels and nodules attached to the pleural wall remain difficult to segment automatically and show low reproducibility, especially for Stage III and Stage IV disease. Work is in progress to improve the automatic segmentation and reproducibility in these cases.

A possible solution may come from “crowd-sourcing” the solutions via “segmentation challenges”: public databases for comparing segmentation results via standard metrics. However, there are intellectual property issues that arise from this type of approach. The patentability of an invention stemming from a public database is a complicated matter that depends upon a number of factors, including inventorship

and the source of funding. In the context of a crowd-sourced development, it may be difficult to identify the “inventors.” It should be noted, however, that there are multiple forms of patent protection, e.g., method patents protecting a particular way of achieving a given result (e.g., an algorithm) or patents covering the particular use of a method. The potential for commercial development may depend only on the resourcefulness of inventors, and the type and scope of the potential patent granted.

Manually traced segmentations are often used as gold standard or ground truth [30] against which the accuracy of the automatic segmentation is evaluated. However, manually traced boundaries themselves suffer from significant inter-reader bias, and the reproducibility is low. In a large image data set and especially with slices thickness 3.0 mm or less where number of slices may be higher than 200 per patient, the option of tracing manual boundaries is time prohibitive. Therefore, it is important to have a segmentation algorithm which is automatic and reproducible. The reproducibility of a manual or automatic segmentation of tumors is a known issue. Inter- and intrareader reproducibility significantly varies. As discussed earlier, in radiomics, sources of variations come from acquisition of images, segmentation and analysis, and should be minimized.

3.2. Segmentation algorithms

Many popular segmentation algorithms have been applied in medical imaging studies within the last 20 years; the most popular ones include region-growing methods [31,32], level set methods [33–38], graph cut methods [39–44], active contours (snake) algorithms [45–49] and semiautomatic segmentations such as livewires [50–53], etc.

Region-growing algorithms are rapid, but undesired “regions” will be produced if the image contains too much noise. The level set method was initially proposed by Osher and Sethian in 1988 to track moving interfaces, and it was subsequently applied across various imaging applications in the late 1990s [38]. By representing a contour as the zero




Fig. 6. Representative examples of lung tumors attached to anatomical structures like pleural wall, mediastinum or heart that are difficult to segment automatically.

level set of a higher dimensional function (level set function), level set method formulates the motion of the contour as the evolution of the level set function. The graph cut method is relatively new in the area of image segmentation, which constructs an image-based graph and achieves a globally optimal solution of energy minimization functions. Since graph cut algorithms try to identify a global optimum, it is computationally expensive. Another problem for graph cut is the oversegmentation.

The active contours (snake) algorithm works like a stretched elastic band being released. The start points are defined around the object which needs to be extracted. The points then move through an iterative process to a point with the lowest energy function value. The active contours algorithm requires a good initialization; it is also sensitive to noise, which may lead the snake to undesired locations. The livewire (intelligent scissor) method is motivated by the general paradigm of the active contour algorithm: it converts the segmentation problem into an optimal graph search problem via local active contour analysis, and its cost function is minimized by using dynamic programming. A problem with the livewire approach is that it is semiautomatic, requiring multiple human interactions.

There is no universal segmentation algorithm that can work for all medical image applications. With proper parameters settings, each segmentation could segment the region of interest automatically or semiautomatically. However, the result of each segmentation will be quite different, and even for the same algorithm performed multiple times with different initializations, results may be variable. Hence, it is very important to develop agreed-upon metrics to evaluate segmentation algorithms.

3.3. Performance metrics

Accuracy, reproducibility and consistency are three of the most important factors to evaluate a segmentation algorithm for medical images. However, conventional evaluation metrics normally utilize the manual segmentation provided by radiologists, which is subjective, error prone and time consuming. In the majority of cases, manual segmentation tends to overestimate the lesion volume to ensure the entire lesion is identified [54], and the process is highly variable [55,56]. In other words, "ground truth" segmentation does not exist. Hence, we believe that reproducibility and consistency are more important than accuracy. That is, for a given a tumor, an algorithm must reproducibly provide the same segmentation results that are user independent.

There is no consensus on the metrics for evaluation of image segmentation algorithms. The metric should address the particular characteristic of the algorithm to be compared, as automated as possible, quantitative and easily computed. Many metrics have been used, like volume, center of volume and maximum surface distance, to compare characteristics like robustness and accuracy [57,58].

The Jaccard Similarity Index (SI) is the measure of the overlap of two or more volumes and is calculated as the ratio of voxel-wise intersection to union of target and reference images [59]:

$$SI_{ab} = \frac{S_a \cap S_b}{S_a \cup S_b}, \quad (1)$$

where S_a and S_b are segmentations of target and reference images, respectively. An SI of 1.0 represents complete overlap (volume, location and shape), and 0 means no overlap. In our current project, we have calculated SI between each pair of 20 independent computer-generated segmentations of individual lung tumors and report the average SI for each lesion, calculated using following equation:

$$\text{Average } SI_i = \frac{1}{20} \sum_{m=1}^{20} \left[\frac{1}{19} \sum_{n \neq m, n=1}^{20} SI_{i_m, i_n} \right], \quad (2)$$

where $i \in [1, \#ofcases]$ is the case index, SI_{i_m, i_n} is from Eq. (1). For manual segmentations, the average SI was 0.73. For automated segmentations, the average SI was 0.93.

4. Feature extraction and qualification

Once tumor regions are defined, imaging features can be extracted. These features describe characteristics of the tumor intensity histogram (e.g., high or low contrast), tumor shape (e.g., round or spiculated), texture patterns (e.g., homogeneous or heterogeneous), as well as descriptors of tumor location and relations with the surrounding tissues (e.g., near the heart).

4.1. Tumor intensity histogram

Tumor intensity histogram-based features reduce the three-dimensional (3D) data of a tumor volume into a single histogram. This histogram describes the fractional volume for a selected structure for the range of voxel values (e.g., Hounsfield units for a CT scan or SUVs for an FDG-PET scan). From this histogram, common statistics can be calculated (e.g., mean, median, min, max, range, skewness, kurtosis), but also more complex values, such as metabolic volume above an absolute SUV of 5 or the fraction of high-density tissue measured with CT [60,61]. Such threshold values have shown promise in developing classifier models, and optimum thresholds for a given task can be identified with receiver operator characteristic (ROC) analyses. As the outcome (e.g., time to recurrence) to which the threshold is being compared can also have a variable threshold, 3D ROC approaches have been developed to represent a surface to optimize both the biomarker and the outcome thresholds.

4.2. Shape-based features

Quantitative features describing the geometric shape of a tumor can also be extracted from the 3D surface of the rendered volumes [62]. For example, the total volume or surface area can be an important characteristic. Also, the surface-to-volume ratio can be determined, where a speculated tumor has a higher value than a round tumor with a similar volume. Furthermore, descriptors of tumor compactness and shape (sphericity, etc.) can also be calculated [63].

4.3. Texture-based features

Second-order statistics or co-occurrence matrix features can be used for texture classification [64–66] and are widely applied in medical pattern recognition tasks [67–71]. The basis of the co-occurrence features lies on the second-order joint conditional probability density function $P(i,j;a,d)$ of a given texture image. The elements (i,j) of the co-occurrence matrix for the structure of interest represent the number of times that intensity levels i and j occur in two voxels separated by the distance (d) in the direction (a) . Here, a matrix can be selected to cover the 26-connected directions of neighboring voxels in 3D space. The matrix size is dependent on the intensity levels within the 3D structure. Subsequently, from this conditional probability density function, features can be extracted, e.g., describing autocorrelation, contrast, correlation, cluster prominence, cluster shade, cluster tendency, dissimilarity, energy, homogeneity, maximum probability, sum of squares, sum average, sum variance, sum entropy or difference entropy, etc. Furthermore, gray level run length features, derived from run length matrices and using run length metrics as proposed by Galloway [66], can be extracted. A gray level run is the length, in number of pixels, of consecutive pixels that have the same gray level value. From the gray level run length matrix, features can be extracted describing short and long run emphasis, gray level nonuniformity, run length non-uniformity, run percentage, low gray level run emphasis and high gray level run emphasis. As expected, such analyses can generate hundreds of variables, some of which may be redundant. Thus, it is important to assess the redundancy of these data using covariance.

4.4. Feature qualification

As described above, a dauntingly large number of image features may be computed. However, all these extracted features may not be useful for a particular task. In addition, the numbers of extracted features can be higher than the number of samples in a study, reducing power and increasing the probability of overfitting the data. Therefore, dimensionality reduction and selection of task-specific features for best performance are necessary steps. Different feature selection methods can be used for this purpose and may exploit machine learning or statistical approaches [72–76].

Dimensionality reduction can also be achieved by combining or transforming the original features to obtain a new set of features by using methods like principal component analysis (PCA) [73]. In addition to feature selection for informative and nonredundant features, high reproducibility of the features is important in the development of clinical biomarkers, which requires the availability of a test–retest data set.

To reduce the dimensionality of our feature space, we have chosen to combine different ad hoc methods that are agnostically applied to the behavior of the features themselves prior to evaluating their ability to develop predictive models. Thus, we evaluated features to fulfill three main requirements: highly reproducible, informative and nonredundant. We have applied three methods in serial manner, where the methods were applied successively to select features. The resulting features of one method were used as input to the next. First, using a test–retest lung CT image data set, highly reproducible features were selected based on concordance correlation coefficient, CCC, with a cutoff of 0.85 for high reproducibility. Subsequently, the CCC-prioritized features were analyzed for dynamic range, calculated as the ratio of scalar biological range to the test–retest absolute difference. Features showing high dynamic range were considered to be informative. A dynamic range of, e.g., 100 can be arbitrarily used as a cutoff, although features with lower dynamic range may also be informative. Finally, the redundancy in the features, selected after passing through reproducibility and dynamic range requirements, can be reduced by identifying highly correlated features based on correlation coefficients across all samples. Correlation coefficients greater than 0.95 are considered to be highly redundant and thus can be combined into a single descriptor. In a test set, the serial application of these three methods was able to reduce a set of 327 quantitative features to 39 that were reproducible, informative and not redundant. More features could be added by relaxing the dynamic range threshold, which was arbitrarily set at 100. These selected features can also be used to develop classifier models based on machine learning algorithms to improve the performance [29].

5. Databases and data sharing

5.1. Deidentification

To follow the principle of providing the minimum amount of confidential information (i.e., patient identifiers) necessary to accommodate downstream analysis of imaging data, raw DICOM image data can be stripped of identified headers and assigned a deidentified number. Maintaining deidentified images and clinical data is an important patient privacy safeguard [77]. In the context of DICOM images, Supplement 142 from the DICOM Standards Committee provides guidance in the process of deidentifying images, including pixel-level data. Software packages, including NBIA [78], implement these standards. Likewise, molecular data can be

deidentified using a similar approach. However, identifiers must be linked between imaging, molecular data and clinical data in order to build classifier models. This can be achieved through institutional review board approval or through the more expedient use of an “honest broker.” The clinical data are deidentified by removing personal identifiers (including medical record numbers, patient names, social security numbers and addresses) and providing calculated interval-based survival times instead of actual dates which are also personal identifiers. The approach taken within our radiomics effort is to avoid the use of identified imaging or clinical data unless specifically required. This also facilitates the sharing of data within and across institutions since the deidentification occurs at the creation of the data set.

5.2. RDB: an integrated radiomics database

The goal of radiomics is to link the image features to phenotypes or molecular signatures, and this requires development of an integrated database wherein the images and the extracted features are linked to clinical and molecular data (Fig. 7). The use of such a database must also be integrated in the workflow starting from image retrieval and calculation of image features up to the joint analysis of image features, clinical data and molecular data. Furthermore, as part of a larger network of quantitative imaging sites, we must also be able to exchange data according to an evolving set of standards. Below are some of the challenges discussed in more detail.

5.2.1. Image storage

Using clinical Picture Archiving and Communications Systems (PACS) systems is not amenable for research projects. First, the clinical system is used for operational

purposes, and introducing additional Input/Output (I/O) load and increased storage could negatively impact clinical care. Second, the requirements between research and clinical systems are different and often incompatible. The research image storage server needs to be fully integrated with the downstream data, including molecular and clinical research data. If the imported DICOM images contain Medical Records Numbers, these need to be linked to other clinical data that are stored on other systems, and then the DICOM headers will be deidentified (e.g., patient name). This allows for transparent merging of clinical data across systems. In a research setting, some of the analyses or imaging feature generation software packages also need direct access to the DICOM images. Having direct access to the file system where the images are stored makes it possible to create project folders, with all images selected for a specific project, which are specific for the software used for the image feature extraction. In our instance, we are using open-source Clear Canvas as a research PACS system, although others are available.

5.2.2. Integration to create a simple work stream

In a research setting, it is common that several different software packages are used for image analysis (e.g., 3D-Slicer, Definiens Developer, Medical Imaging Toolkit [MITK]) and statistical analysis (e.g., R, SAS, Stata). Many of these software packages may be developed by industry, in-house or by other academic groups. This requires that the RDB import data from analysis projects using these software packages in a simple way without sacrificing data integrity. This can be achieved by having the RDB application directly reading working directories and/or results files from the software used. If unique tags have been used when creating




Fig. 7. Architecture of the proposed RDB. High-level database schema capturing the following data types: image types (orange), image features (purple), patient/clinical (blue) and molecular (green) data. Each box represents a set of normalized tables. This schema supports multiple tumors for one patient, with multiple images series, using multiple segmentations generating different image features.

image filenames, it is easy to link these data with the right image and downstream clinical and molecular data.

5.2.3. Integration of clinical and molecular data

Integrating data across systems is always a challenge in large settings. The RDB application needs to integrate the data from several systems, such as outcomes and demographic data (Cancer Registry), clinical trial data (e.g., Oncore) or other systems that store clinical and patient information. The manual input of such data should be kept to a minimum through the use of an extract, transform and load tool that captures the physical metadata information to maintain data provenance and minimizes the risk of human errors. The use of a well-developed data dictionary with extensive metadata is essential when integrating data across systems. Therefore, a new data warehouse model that incorporates the metadata layer into the data model, including a comprehensive data dictionary along with calculated data quality attributes such as completeness, accuracy and consistency, has been utilized for the radiomics project [79]. This new data structure was specifically designed to provide easy semantic integration of internal data from multiple heterogeneous source systems as well as provide an easy solution for harmonizing clinical, molecular and imaging data with external members of the quantitative imaging network. Along this path, it has also been important to ensure that the RDB structure and semantics are compatible with those from other institutions and (inter) national databases.

5.2.4. Reporting and exporting the data

Advanced statistical analyses of radiomics data require tools such as R, SAS, or MATLAB. The application must be able to export data in such a way that it minimizes any need for processing of data outside the RDB application and thus keeping the data aligned and correct. Longitudinal studies add an extra layer of complexity with the potential need of reporting changes over time, such as imaging features or clinical parameters. A flexible selection of which data should be included and in which format the data should be exported is important.

6. Statistical and radioinformatics analysis

Analysis within radiomics must evolve appropriate approaches for identifying reliable, reproducible findings that could potentially be employed within a clinical context. Applying the existing bioinformatics “toolbox” to radiomics data is an efficient first step since it eliminates the necessity to develop new analytical methods and leverages accepted and validated methodologies. Radiomics-specific analysis issues will exist, as in any field; therefore, an important step in achieving consensus on appropriate analysis and evaluation techniques requires availability of real-world data. The goals of the Quantitative Imaging Network (QIN) in providing infrastructure to effectively

share radiomics data will enable the further development of methodology and best practices within the field.

Some of the more significant methods or developments from the bioinformatics toolbox include (a) multiple testing issues, (b) supervised and unsupervised analysis and (c) validating biomarker classifiers. Another important analytical consideration is the incorporation of clinical and patient risk factor data since they may have a causal effect or correlation with image features or they may confound statistical associations. Thus, synergizing biostatistics, epidemiology and bioinformatics approaches is necessary to build robust, parsimonious and clinically relevant predictive models relating image features to phenotypes/end points or gene–protein signatures.

6.1. High-dimensional biomarker discovery and validation

The field of high-dimensional biomarker discovery and validation has evolved rapidly over the past decade since some of the earliest microarray-based results were reported [80]. In particular, these advances have prompted many studies to address clinical prediction (e.g., prognosis, response to therapy). Many of the lessons learned and tools developed within this field are immediately relevant to the analysis of radiomics data sets.

6.1.1. Multiple testing

Many of the significant developments within the field of so-called “large- p , small- n ” data analysis problems are robust methods for accommodating multiple testing issues. In many data sets in these areas, it is not unusual to test the significance of tens of thousands of variables ($p=50,000$) using a univariate test (e.g., a t test) across 50 samples ($n=50$). Any single test may have a low expected false-positive rate; however, the cumulative effect of many repeated tests guarantees that many statistically significant findings are due to random chance. The false positives (type I errors in statistics) are controlled using an appropriate P value threshold (e.g., $P<.05$) in the case of single test. However, performing 50,000 tests creates serious concerns over the accumulated type I error from such an experiment. This multiple testing problem has been addressed in statistics in many ways; however, the most familiar, and conservative, Bonferroni corrections severely limit the power of the test in the 50,000-test experiments [81]. False discovery rates [82–84] have been developed to provide more reasonable error estimates. Incorporating this type of correction is an essential step, even in discovery-oriented analysis, to give researchers reasonable guidance on the validity of their discoveries.

6.1.2. Unsupervised and supervised data analysis

Depending on the type of analysis, there are both unsupervised and supervised analysis options available. The distinction in these approaches is that unsupervised analysis does not use any outcome variable, but rather provides summary information and/or graphical representations of

the data. Supervised analysis, in contrast, creates models that attempt to separate or predict the data with respect to an outcome or phenotype (for instance, patient outcome or response).

Clustering is the grouping of like data [85] and is one of the most common unsupervised analysis approaches. There are many different types of clustering, although several general types are commonly used within bioinformatics approaches. Hierarchical clustering, or the assignment of examples into clusters at different levels of similarity into a hierarchy of clusters, is the most common type. Similarity is based on correlation (or Euclidean distance) between individual examples or clusters. Most significantly, the data from this type of analysis can be graphically represented using the cluster heat map. Fig. 8 represents a heat map of NSCLC patients with quantitative imaging features extracted. The heat map is an intuitive display that simultaneously reveals row and column hierarchical cluster structure in a data matrix that consists of a rectangular tiling with each tile shaded on a color scale to represent the value of the corresponding element of the data matrix. This cluster heat map is a synthesis of various graphic displays developed by statisticians over more than a century [86].

Supervised analysis consists of building a mathematical model of an outcome or response variable. The breadth of techniques available is remarkable and spans statistics and data mining/machine learning. Approaches we have used include neural networks [87], linear regression [87] and Cox proportional hazards regression [88]. Some essential criteria in selecting an approach include the stability and reproducibility of the model. Neural networks or ensemble methods, if they involve an element of randomness, can lead to results that cannot be replicated without the same random sequences generated. In light of many of the difficulties surrounding genomic-based models, understandability of the generated models is an important consideration. For clinical validation, alternate assays or measurements may be required, and thus, an understanding of the way in which variables are combined in a decision model is necessary for translation. In the case of NSCLC imaging, methods that generate understandable decisions can be important for combining this information with existing advances in genotyping patients (e.g., EGFR mutation, EML4-ALK rearrangements).

Multivariate data analysis tools such as PCA [89] and partial least squares projection to latent structures [90] (PLS) can be used to analyze quantitative features together with additional data. PCA allows for an unsupervised analysis of the data where important features can be extracted and visualized. PCA extracts the underlying structures, principal components, so that a high-dimensional space can be visualized in a 2D or 3D space. Additional layers of information can be added by using coloring, shapes and size of the objects on the graphs. PCA can be utilized to find grouping, outliers and other artifacts within the data. To find

common underlying structures and correlation between two matrices, PLS can be used. PLS has been shown to work well on large and complex data sets with more variables than observations, on collinear variables and where there are some missing data.

A final, key contribution from the field of bioinformatics is the approach developed to provide validation of prediction findings from high-dimensional experiments. As was noted in Ref. [91], many genomics-based studies that have been published contain significant analytical errors. These errors compromise the estimates of predictor accuracy or overall findings. Following the best practices in developing and then independently validating the observations in a distinct cohort is essential for reproducible results [92]. For instance, in our radiomics study, we have provided for several validation components, including validation between MAASTRO Clinic (Netherlands) and Moffitt sample sets, as well as validation in prospectively collected Moffitt samples. When model building and cross-validation efforts are completed, the entire group will determine the appropriate model(s) to evaluate in independent validation.

6.1.3. Sample size issues

High-throughput technologies (CT images, genomic/proteomic, etc.) provide us with an enormous amount of multivariate data describing the complex biological process. Ability to predict risks or to draw inferences based on clinical outcomes is bogged by sample size. Efron et al. have pioneered the work, studied various cross-validation methods and proposed unbiased error estimation called the bootstrap [93,94]. Inference in small samples has seen renewed interest with the advent of genomics technologies, especially in classification [95]. There has been extensive studies to make unbiased inference in small samples, one approach was to create synthetic samples following the distribution of the sample groups and report errors of the newly formed population [96]. In addition, most popular error estimates has been studied in context of small sample classification [97].

6.2. Clinical and risk factor data

Incorporating detailed clinical and patient risk factor data into radiomics is important because imaging features may be influenced by patient parameters. Patient parameters may influence the image features via a direct causal association or exert a confounding effect on statistical associations whereby the parameter is correlated with both the independent and dependent variables. For instance, smoking-related lung cancers differ from lung cancers in patients who never smoked, and thus, smoking status could influence image features, clinical parameters (histology), phenotypes, molecular signatures and end points (i.e., survival, recurrence). Addressing the influence of patient parameters in radiomics research by using epidemiologic and biostatistical approaches will minimize spurious relationships by avoiding type I error. Moreover, predictive




Fig. 8. Unsupervised hierarchical clustering of lung tumor image features extracted from CT images from 276 NSCLC patients. Tumor segmentation for each CT image was performed in a semiautomated fashion. Quantitative imaging features were calculated using Definiens (Munich, Germany) and represent many 2D and 3D characteristics of the tumor. Aspects such as tumor volume, shape and texture were represented. Each of the numerical imaging features was median centered, and all features were clustered using complete linkage, with correlation used as the similarity measure. The resulting heat map is visualized using red to represent higher than median feature values and green to represent lower than median feature values. Each row of the heat map represents a specific imaging feature across patients, and each column represents all features for a patient's lung tumor from CT.

models which are more precise and clinically relevant may be developed which target well-characterized and -defined patient subgroups rather than a broad heterogeneous disease group. For example, a model that includes all patients with adenocarcinoma of lung would not likely be clinically relevant because of the heterogeneity (biological and clinical) of this histologic subtype. However, a predictive model which focused on adenocarcinoma patients with a specific molecular feature (e.g., EML4-ALK fusion) would likely be informative because of the biological and clinical homogeneity and subsequent targeted therapies. Thus, as noted with the bioinformatics “toolbox,” existing epidemiologic and biostatistical approaches can be leveraged towards radiomics research to develop robust and clinically relevant prognostic models, to reveal factors that may influence (casually or by confounding) radiomics features, and to explore and mine complex data sets.

Acknowledgment

Radiomics of NSCLC U01 CA143062.

References

- [1] Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Stiphout RV, Granton P, et al. Radiomics: extracting more information from medical images using advance feature analysis. *Eur J Cancer* 2012;48(4): 441–6.
- [2] Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. *J Clin Oncol* 2006;24(20):3245–51.
- [3] Burton A. RECIST: right time to renovate? *Lancet Oncol* 2007;8(6): 464–5.
- [4] Rubin DL. Creating and curating a terminology for radiology: ontology modeling and analysis. *J Digit Imaging* 2008;21(4):355–62.
- [5] Opulencia P, Channin DS, Raicu DS, Furst JD. Mapping LIDC, RadLex™, and lung nodule image features. *J Digit Imaging* 2011;24(2):256–70.
- [6] Channin DS, Mongkolwat P, Kleper V, Rubin DL. The annotation and image mark-up project 1. *Radiology* 2009;253(3):590–2.
- [7] Rubin DL, Mongkolwat P, Kleper V, Supekar K, Channin DS. Medical imaging on the semantic web: annotation and image markup. 2008. AAAI Spring Symposium Series, Semantic Scientific Knowledge Integration, Stanford University, 2008.
- [8] Jackson A, O'Connor JPB, Parker GJM, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. *Clin Cancer Res* 2007;13(12): 3449–59.
- [9] Rose CJ, Mills SJ, O'Connor JPB, Buonaccorsi GA, Roberts C, Watson Y, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. *Magn Reson Med* 2009;62(2):488–99.
- [10] Gibbs P, Turnbull LW. Textural analysis of contrast-enhanced MR images of the breast. *Magn Reson Med* 2003;50(1):92–8.
- [11] Canuto HC, McLachlan C, Kettunen MI, Velic M, Krishnan AS, Neves AA, et al. Characterization of image heterogeneity using 2D Minkowski functionals increases the sensitivity of detection of a targeted MRI contrast agent. *Magn Reson Med* 2009;61(5):1218–24.
- [12] Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. *Nat Biotechnol* 2007;25(6):675–80.
- [13] Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. *Proc Natl Acad Sci* 2008;105(13):5213.
- [14] Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. *Eur J Nucl Med Mol Imaging* 2010;37(1):181–200.
- [15] Boellaard R. Standards for PET image acquisition and quantitative data analysis. *J Nucl Med* 2009;50(Suppl. 1):11S–20S.
- [16] Ollers M, Bosmans G, van Baardwijk A, Dekker A, Lambin P, Teule J, et al. The integration of PET–CT scans from different hospitals into radiotherapy treatment planning. *Radiother Oncol* 2008;87(1):142–6.
- [17] Janssen MH, Ollers MC, van Stiphout RG, Riedl RG, van den Bogaard J, Buijns J, et al. Blood glucose level normalization and accurate timing improves the accuracy of PET-based treatment response predictions in rectal cancer. *Radiother Oncol* 2010;95(2):203–8.
- [18] Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. *Neoplasia* 2009;11(2): 102–25.
- [19] Delakis I, Moore EM, Leach MO, De Wilde JP. Developing a quality control protocol for diffusion imaging on a clinical MRI system. *Phys Med Biol* 2004;49(8):1409–22.
- [20] Yang X, Knopp MV. Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. *J Biomed Biotechnol* 2011;2011:732848.
- [21] Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. *NMR Biomed* 2002;15(2):132–42.
- [22] Makkat S, Luytjaert R, Sourbron S, Stadnik T, De Mey J. Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data. *J Magn Reson Imaging* 2007;25(6):1159–67.
- [23] Yang C, Stadler WM, Karczmar GS, Milosevic M, Yeung I, Haider MA. Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. *Magn Reson Med* 2010;63(6):1601–9.
- [24] Priest AN, Gill AB, Kataoka M, McLean MA, Joubert I, Graves MJ, et al. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. *Magn Reson Med* 2010;63(4):1044–9.
- [25] McGrath DM, Bradley DP, Tessier JL, Lacey T, Taylor CJ, Parker GJ. Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. *Magn Reson Med* 2009;61(5):1173–84.
- [26] Jackson E, Ashton E, Evelhoch J, Buonocore M, Karczmar G, Rosen M, et al. Multivendor, multisite DCE-MRI phantom validation study. 2009. In: Proceedings of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA '10); December 2009; Chicago, IL, USA.
- [27] Armato III SG, McLennan G, Hawkins D, Bidaut L, McNitt-Gray MF, Meyer CR, et al. The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. *Med Phys* 2011;38(2):915–31.
- [28] Armato III SG, Meyer CR, McNitt-Gray MF, McLennan G, Reeves AP, Croft BY, et al. The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software. *Clin Pharmacol Ther* 2008;84(4):448–56.
- [29] Basu S, Hall L, Goldgof D, Gu Y, Kumar V, Choi J, et al. Developing a classifier model for lung tumors in CT-scan images. *IEEE International Conference on Systems, Man and Cybernetics (SMC 2011)*, Anchorage, Alaska, 10/2011.
- [30] Stroom J, Blaauwgeers H, van Baardwijk A, Boersma L, Lebesque J, Theuvs J, et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. *Int J Radiat Oncol Biol Phys* 2007;69(1):267–75.
- [31] Hojjatoleslami S, Kittler J. Region growing: a new approach. *IEEE Trans Image Process* 1998;7(7):1079–84.

- [32] Dehmeshki J, Amin H, Valdivieso M, Ye X. Segmentation of pulmonary nodules in thoracic CT scans: a region growing approach. *IEEE Trans Med Imaging* 2008;27(4):467–80.
- [33] Sethian JA. Level set methods and fast marching methods: evolving interfaces in computational geometry, fluid mechanics, computer vision, and materials science. 2nd ed. Cambridge: Cambridge University Press; 1999.
- [34] Malladi R, Sethian JA, Vemuri BC. Shape modeling with front propagation: a level set approach. *IEEE Trans Pattern Anal Mach Intell* 1995;17(2):158–75.
- [35] Gao H, Chae O. Individual tooth segmentation from CT images using level set method with shape and intensity prior. *Pattern Recognition* 2010;43(7):2406–17.
- [36] Chen YT. A level set method based on the Bayesian risk for medical image segmentation. *Pattern Recognition* 2010;43(11):3699–711.
- [37] Krishnan K, Ibanez L, Turner WD, Jomier J, Avila RS. An open-source toolkit for the volumetric measurement of CT lung lesions. *Opt Express* 2010;18(14):15256–66.
- [38] Osher S, Sethian JA. Fronts propagating with curvature-dependent speed: algorithms based on Hamilton–Jacobi formulations. *J Comput Phys* 1988;79(1):12–49.
- [39] Boykov Y, Veksler O, Zabih R. Fast approximate energy minimization via graph cuts. *IEEE Trans Pattern Anal Mach Intell* 2001;23(11):1222–39.
- [40] So RWK, Tang TWH, Chung A. Non-rigid image registration of brain magnetic resonance images using graph-cuts. *Pattern Recognition* 2011;2450–67.
- [41] Xu N, Bansal R, Ahuja N. Object segmentation using graph cuts based active contours. *IEEE* 2003;42:II-46–53.
- [42] Slabaugh G, Unal G. Graph cuts segmentation using an elliptical shape prior. *IEEE* 2005;II-1222–5.
- [43] Liu X, Veksler O, Samarabandu J. Graph cut with ordering constraints on labels and its applications. *IEEE* 2008:1–8.
- [44] Ye X, Beddoe G, Slabaugh G. Automatic graph cut segmentation of lesions in CT using mean shift superpixels. *J Biomed Imaging* 2010;2010:19.
- [45] Liu W, Zagzebski JA, Varghese T, Dyer CR, Techavipoo U, Hall TJ. Segmentation of elastographic images using a coarse-to-fine active contour model. *Ultrasound Med Biol* 2006;32(3):397–408.
- [46] He Q, Duan Y, Miles J, Takahashi N. A context-sensitive active contour for 2D corpus callosum segmentation. *Int J Biomed Imaging* 2007;2007(3):24826.
- [47] Chen C, Li H, Zhou X, Wong S. Constraint factor graph cut–based active contour method for automated cellular image segmentation in RNAi screening. *J Microsc* 2008;230(2):177–91.
- [48] Suzuki K, Kohlbrenner R, Epstein ML, Obajuluwa AM, Xu J, Hori M. Computer-aided measurement of liver volumes in CT by means of geodesic active contour segmentation coupled with level-set algorithms. *Med Phys* 2010;37:2159.
- [49] Wang L, Li C, Sun Q, Xia D, Kao CY. Active contours driven by local and global intensity fitting energy with application to brain MR image segmentation. *Comput Med Imaging Graph* 2009;33(7):520–31.
- [50] Mortensen EN, Barrett WA. Interactive segmentation with intelligent scissors. *Graph Models Image Process* 1998;60(5):349–84.
- [51] Souza A, Udupa JK, Grevera G, Sun Y, Odhner D, Suri N, Schnall MD. Iterative live wire and live snake: new user-steered 3D image segmentation paradigms. In: *Medical Imaging 2006: Image Processing*. Reinhardt JM, Pluim JP, editors. Proceedings of the SPIE, 2006;6144:1159–1165.
- [52] Lu K, Higgins WE. Interactive segmentation based on the live wire for 3D CT chest image analysis. *Int J Comput Assist Radiol Surg* 2007;2(3):151–67.
- [53] Lu K, Higgins WE. Segmentation of the central-chest lymph nodes in 3D MDCT images. *Comput Biol Med* 2011;41(9):780–9. Epub 2011 Jul 12.
- [54] Rexilius J, Hahn HK, Schluter M, Bourquain H, Peitgen HO. Evaluation of accuracy in MS lesion volumetry using realistic lesion phantoms. *Acad Radiol* 2005;12(1):17–24.
- [55] Tai P, Van Dyk J, Yu E, Battista J, Stitt L, Coad T. Variability of target volume delineation in cervical esophageal cancer. *Int J Radiat Oncol Biol Phys* 1998;42(2):277–88.
- [56] Cooper JS, Mukherji SK, Toledano AY, Beldon C, Schmalfluss IM, Amdur R, et al. An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). *Int J Radiat Oncol Biol Phys* 2007;67(4):972–5.
- [57] Jameson MG, Holloway LC, Vial PJ, Vinod SK, Metcalfe PE. A review of methods of analysis in contouring studies for radiation oncology. *J Med Imaging Radiat Oncol* 2010;54(5):401–10.
- [58] Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation. *IEEE Trans Med Imaging* 2004;23(7):903–21.
- [59] Zijdenbos AP, Dawant BM, Margolin RA, Palmer AC. Morphometric analysis of white matter lesions in MR images: method and validation. *IEEE Trans Med Imaging* 1994;13(4):716–24.
- [60] Holub O, Ferreira ST. Quantitative histogram analysis of images. *Comput Phys Commun* 2006;175(9):620–3.
- [61] El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. *Pattern Recognition* 2009;42(6):1162–71.
- [62] O’Sullivan F, Roy S, O’Sullivan J, Vernon C, Eary J. Incorporation of tumor shape into an assessment of spatial heterogeneity for human sarcomas imaged with FDG-PET. *Biostatistics* 2005;6(2):293–301.
- [63] Jain AK. *Fundamentals of digital image processing*. New Jersey: Prentice-Hall, Inc.; 1988.
- [64] Lam SWC. Texture feature extraction using gray level gradient based co-occurrence matrices. *IEEE* 1996;261:267–71.
- [65] Haralick RM, Shanmugam K, Dinstein IH. Textural features for image classification. *IEEE Trans Syst Man Cybern* 1973;3(6):610–21.
- [66] Galloway MM. Texture analysis using gray level run lengths. *Comput Graph Image Process* 1975;4(2):172–9.
- [67] Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. *Clin Radiol* 2004;59(12):1061–9.
- [68] Zinovev D, Raicu D, Furst J, Armato III SG. Predicting radiological panel opinions using a panel of machine learning classifiers. *Algorithms* 2009;2(4):1473–502.
- [69] Soh LK, Tsatsoulis C. Texture analysis of SAR sea ice imagery using gray level co-occurrence matrices. *IEEE Trans Geosci Remote Sens* 1999;37(2):780–95.
- [70] Suárez J, Gancedo E, Álvarez JM, Morán A. Optimum compactness structures derived from the regular octahedron. *Engineering Structures* 2008;30(11):3396–8.
- [71] Tang X. Texture information in run-length matrices. *IEEE Trans Image Process* 1998;7(11):1602–9.
- [72] Kramer K, Goldof DB, Hall LO, Remsen A. Increased classification accuracy and speedup through pair-wise feature selection for support vector machines. *IEEE* 2011:318–24.
- [73] Song F, Guo Z, Mei D. Feature selection using principal component analysis. *Yichang IEEE* 2010:27–30.
- [74] Heshmati A, Amjadifard R, Shanbehzadeh J. ReliefF-based feature selection for automatic tumor classification of mammogram images. *Tehran IEEE* 2011:1–5.
- [75] Jain A, Zongker D. Feature selection: evaluation, application, and small sample performance. *IEEE Trans Pattern Anal Mach Intell* 1997;19(2):153–8.
- [76] Fu J, Lee SK, Wong STC, Yeh JY, Wang AH, Wu H. Image segmentation feature selection and pattern classification for mammographic microcalcifications. *Comput Med Imaging Graph* 2005;29(6):419–29.
- [77] Liu J, Erdal S, Silvey SA, Ding J, Riedel JD, Marsh CB, et al. Toward a fully de-identified biomedical information warehouse. *AMIA Annu Symp Proc* 2009;2009:370–4.
- [78] Freymann JB, Kirby JS, Perry JH, Clunie DA, Jaffe CC. Image data sharing for biomedical research — meeting HIPAA requirements for de-identification. *J Digit Imaging* 2012;25(1):14–24.

- [79] Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. *Cancer J* 2011;17(6):528–36.
- [80] Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science* 1999;286(5439):531–7.
- [81] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B* 1995;289–300.
- [82] Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 2001;98(9):5116–21.
- [83] Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. *Ann Stat* 2003:2013–35.
- [84] Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. *Bioinformatics* 2003;19(3):368–75.
- [85] Jain A, Dubes R. Algorithms that cluster data. Englewood Cliffs, NJ: Prentice Hall; 1988.
- [86] Wilkinson L, Friendly M. The history of the cluster heat map. *Am Stat* 2009;63(2):179–84.
- [87] Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. *J Clin Oncol* 2005;23(15):3526–35.
- [88] Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nat Med* 2008;14(8):822–7.
- [89] Jolliffe IT. Principal component analysis. 2nd ed. New York: Springer; 2002.
- [90] Wold S, Ruhe A, Wold H, Dunn III W. The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. *SIAM J Sci Statist Comput* 1984;5:735.
- [91] Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. *J Natl Cancer Inst* 2007;99(2):147–57.
- [92] Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst* 2009;101(21):1446–52.
- [93] Efron B. Bootstrap methods: another look at the jackknife. *Ann Stat* 1979;7(1):1–26.
- [94] Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. *J Am Stat Assoc* 1983:316–31.
- [95] Dougherty ER. Small sample issues for microarray-based classification. *Compar Funct Genom* 2001;2(1):28–34.
- [96] Kim S, Dougherty ER, Barrera J, Chen Y, Bittner ML, Trent JM. Strong feature sets from small samples. *J Comput Biol* 2002;9(1):127–46.
- [97] Braga-Neto U, Hashimoto R, Dougherty ER, Nguyen DV, Carroll RJ. Is cross-validation better than resubstitution for ranking genes? *Bioinformatics* 2004;20(2):253–8.